CRNX Crinetics
- 56.690
- +0.730+1.30%
- 56.690
- 0.0000.00%
Crinetics News
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $71
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
LifeSci Capital Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $77
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $80
JMP Securities Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $80
Optimistic Buy Rating for Crinetics Pharmaceuticals on Paltusotine's Potential and Robust Pipeline
Crinetics Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Crinetics Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Prothena (PRTA) and Xenon (XENE)
Buy Rating Affirmed for Crinetics Pharmaceuticals on Strong Pipeline and Regulatory Progress
Oppenheimer Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
Buy Rating for Crinetics Pharmaceuticals: Strong Pipeline and Financial Stability
Strong Future for Crinetics Pharmaceuticals: A Comprehensive Buy Rating Justification
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Elevance Health (ELV) and Johnson & Johnson (JNJ)
JPMorgan Raises Price Target on Crinetics Pharmaceuticals to $54 From $47, Maintains Overweight Rating
Crinetics Pharmaceuticals Analyst Ratings
Crinetics Pharmaceuticals Analyst Ratings
Analysis
Price Target
No Data
No Data